Precision Diagnostics for Personalized Healthcare
Next Generation Sequencing (NGS) is a state-of-the-art technology that decodes DNA and RNA with exceptional speed and accuracy. By analyzing millions of genetic fragments simultaneously, NGS provides deep insights into a person’s genetic makeup—helping clinicians diagnose conditions, guide treatment decisions, and predict health risks.
NGS enables the detection of a wide range of genetic alterations, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions, and complex biomarkers such as MSI, MMR, and TMB. These insights are critical for identifying actionable mutations, selecting targeted therapies, and assessing eligibility for immunotherapy.
Whether applied to solid tumors, hematologic malignancies, or liquid biopsy samples, NGS empowers precision medicine by transforming genomic data into clinically meaningful decisions. Our portfolio of panels is designed to support oncologists, pathologists, and researchers in delivering personalized care with confidence.
NGS Service Overview
The Next Generation Sequencing (NGS) panels are organized by testing approach to support diverse clinical needs. This structure helps clinicians and patients quickly identify the most appropriate test based on diagnostic goals, sample type, and disease focus.
Multiple Solid Tumour Panel
Comprehensive Profiling
This panel is designed to detect genetic mutations common to a wide range of solid tumours, including lung, breast, colorectal, prostate, and ovarian cancers. Ideal for broad-spectrum screening, treatment planning, and identifying eligibility for targeted therapies or clinical trials.
Specific Cancer Panel
Focused Analysis
Tailored panels that target the unique genetic landscape of a specific cancer such as breast cancer (BRCA1/2, HER2), lung cancer (EGFR, ALK), or colorectal cancer (KRAS, NRAS). These tests provide precise insights for diagnosis, prognosis, and personalized treatment strategies.
Liquid Biopsy Panel
Blood-Based Screening
This cutting-edge test analyzes circulating tumor DNA (ctDNA) from a blood sample, offering a minimally invasive method to detect mutations, monitor treatment response, and track disease progression. Ideal for patients unable to undergo tissue biopsy or for real-time surveillance.
 |  |  |
|---|
